Clinical Trial Update: Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme [Phase 2]

View source ↗

Summary

Phase 2 trial of Fabrazyme in Fabry disease patients with severe renal disease was terminated; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease, Chronic Kidney Disease, Stage IV (Severe) | Phase 2 | Status: TERMINATED | Results posted: 2009-02-05